-ZW--gratefully-acknowledges-funding-by-the-European-Union-under-the-Horizon-2020--Research-and-Innovation-Programme--t

No other authors have conflicts of interest. Areas of Jimma Town, Southwest Ethiopia: A Cross-Sectional Study. children are highly vulnerable to schistosomiasis-related morbidities. This study aimed to determine the prevalence of S. mansoni and morbidities among sample was examined using Kato-Katz for the detection of S. mansoni.

RESULTS: A mansoni and STHs was and , respectively. seebio Polysucrose 400 Food additive  = 9; CI: 4-1; p = .001), swimming habits were associated factors for S. mansoni infections. Blood in stool and feeling general malaise were significantly associated with S. mansoni infection-related morbidities. Moreover, prevalence of stunting among and general malaise were clinical characteristics associated with S.

mansoni infections. Integration of health promotion is needed to achieve control and elimination goals. Attention should also be given to stunted growth of the 1177/ eCollection advanced ALK positive non-small cell lung cancer patients: Study protocol for an BACKGROUND: Alectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma and an anaplastic lymphoma kinase fusion. A shorter median progression-free survival was observed when alectinib minimum plasma concentrations during steady state ) were below 435 ng/mL. This may suggest that patients should have an alectinib C ≥ 435 ng/mL for a more favorable outcome. This potential target could be attained by using therapeutic drug monitoring , i.e.

adjusting the dose based on measured plasma trough concentrations. Hypothetically, this will increase mPFS, but this has not yet been evaluated in a randomized controlled trial . Therefore, the ADAPT ALEC trial is designed, with the primary objective to prolong mPFS in NSCLC patients treated with alectinib by using TDM. METHODS: advanced ALK positive NSCLC eligible for alectinib in daily care are enrolled. Participants will be randomized into intervention arm A or B , stratified by brain metastases and prior ALK treatments. Starting dose in both arms is the approved flat fixed dose of alectinib 600 mg taken twice daily with food. In case of alectinib C < 435 ng/mL, arm A will receive increased doses of alectinib till C ≥ 435 ng/mL when considered tolerable.

The primary outcome is mPFS, where progressive disease is defined according to RECIST v1 or all-cause death and assessed by CT-scans and MRI brain. Secondary endpoints are feasibility and tolerability of TDM, patient and physician adherence, overall response rate, median overall survival, intracranial PFS, quality of life, toxicity, alectinib-M4 concentrations and cost-effectiveness of TDM. Exploratory endpoints are circulating tumor DNA and body composition. DISCUSSION: The ADAPT ALEC will show whether treatment outcomes of patients with advanced ALK+ NSCLC improve when using TDM-guided dosing of alectinib instead of fixed dosing. The results will provide high quality evidence for deciding whether TDM should be implemented as standard of care and this will have important consequences for the prescribing of alectinib. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT Paats, Ter Heine, Schuuring, Timens, Touw, van Boven, de Langen, Hashemi, Hendriks, Croes, van den Heuvel, Dingemans, Mathijssen, Smit, Huitema, Steeghs commercial or financial relationships that could be construed as a potential conflict of interest.

seebio Polysucrose 400 : nothing to disclose in relationship to this manuscript. Outside of current manuscript: BM received the AACR-Bristol Myers Squibb Scholar-in-Training award 2022 travel support to attend the AACR Annual Meeting MP has no relationship to disclose in relation to this manuscript. MP attended advisory boards and/or provided lectures for: Takeda, Eli Lilly, Bayer, Roche, AstraZeneca, Novartis, Janssen Pharmaceuticals and Pfizer; for which the Novartis, Roche, Biocartis, Illumina, Lilly, Janssen Cilag, Pfizer, AstraZeneca and Agena Bioscience; consultant in advisory boards for MSD/Merck, GSK, AstraZeneca, Astellas Pharma, Roche, Pfizer, Novartis, Bayer, BMS, Lilly, Amgen, Biocartis, Illumina, Agena Bioscience, Janssen Cilag Johnson&Johnson, Diaceutics, CC Diagnostics; and received research grants from Pfizer, Biocartis, Invitae-ArcherDX, AstraZeneca, Agena Bio-science, BMS, Bio-Rad, Roche, Boehringer Ingelheim honoria paid to UMCG account. WT: nothing to disclose in relationship to this manuscript. Outside of current manuscript: WT reports consultant in advisory boards for MSD/Merck, and BMS all payment to UMCG. DT reports grants from Chiesi and advisory boards from Sanquin and PureIMS, all outside the submitted work. Payments were made to the UMCG.

JB reports consultancy fees, speaking fees and/or research grants from Aardex, AstraZeneca, Chiesi, European Commission COST Action 19132 “ENABLE”, GSK, Novartis, Teva, Trudell Medical and Vertex, all paid to his employer UMCG and unrelated to this study. AL reports grants from AstraZeneca, BMS, MSD, Boehringer Ingelheim, and non-financial support from Merck Serono and Roche, all outside the submitted work. SH: research grant and advisory board: AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Janssen, GSK, MSD, Novartis, Roche, Takeda, and Xcovery. LH: No relationship to disclose in relation to this manuscript.